Anti-SSA in Pregnancy: Congenital Heart Block Risks
Published: | Updated:
For a first pregnancy, the risk of a baby developing congenital heart block from maternal Anti-SSA antibodies is very low (1-2%). Taking hydroxychloroquine and undergoing frequent fetal heart monitoring between weeks 16 and 26 are highly effective ways to protect your baby.
Key Takeaways
- • The risk of congenital heart block in a first pregnancy with Anti-SSA antibodies is very low, at just 1% to 2%.
- • Neonatal lupus is a temporary condition caused by maternal antibodies crossing the placenta, not a lifelong autoimmune disease.
- • Taking hydroxychloroquine during pregnancy significantly reduces the risk of heart block and is considered safe for the baby.
- • The critical window for fetal heart block development is between weeks 16 and 26 of pregnancy.
- • Frequent fetal echocardiograms during the second trimester allow doctors to detect early rhythm changes and intervene with medication.
If you have Anti-SSA (Ro) antibodies, you may be understandably anxious about the risk of your baby developing a heart condition called congenital heart block (CHB). The most important thing to know is that this risk is very low: for a first pregnancy in a mother with Anti-SSA antibodies, there is only a 1% to 2% chance that the baby will develop CHB [1][2][3]. The vast majority of pregnancies in women with these antibodies result in healthy babies with no heart complications at all [4][5].
It is also incredibly important to remember that having these antibodies is completely out of your control. If your baby does experience a heart complication, it is not because of anything you did wrong or failed to do.
How Antibodies Affect the Baby
In mothers with primary Sjögren’s syndrome, certain proteins called autoantibodies—specifically Anti-SSA (Ro) and sometimes Anti-SSB (La)—can cross the placenta during pregnancy. In a very small percentage of cases, these antibodies cause inflammation in the baby’s developing heart tissue. This inflammation can interfere with the electrical signals that tell the baby’s heart to beat, resulting in congenital heart block [6][7].
You might also hear doctors use the term neonatal lupus. This is a terrifying and confusing term for a parent to hear, but it does not mean your baby is being born with a systemic, lifelong autoimmune disease like adult lupus. Instead, it is an umbrella term for the effects of maternal antibodies on the baby. The most common symptoms are a temporary skin rash or minor liver enzyme changes that disappear entirely on their own by the time the baby is one year old, without any lasting effects [4][5]. Congenital heart block is simply the cardiac form of this temporary condition.
Your personal risk for CHB is highest if you have very high levels (titers) of these antibodies [1][8]. Additionally, if you have had a previous pregnancy affected by neonatal lupus or heart block, the risk for future pregnancies increases significantly to about 15% to 20% [9].
Protecting Your Baby: The Role of Hydroxychloroquine
Taking hydroxychloroquine (Plaquenil) during your pregnancy is one of the most effective, evidence-based steps you can take to protect your baby’s heart. Research shows that taking this medication significantly reduces the risk of congenital heart block and other forms of neonatal lupus [9][10][11].
Hydroxychloroquine is believed to work by calming the immune system and blocking the maternal antibodies from attaching to and affecting the fetal heart tissue [12][13]. It is widely considered safe to take throughout pregnancy and is not associated with an increased risk of major birth defects or toxicity to the baby [14][15][16].
Because hydroxychloroquine takes time to build up to protective levels in your system, your medical team will likely recommend starting or continuing it before conception, or as early as possible in your first trimester [17][18].
Your Monitoring Plan: Weeks 16 to 26
Even though the risk is low, your medical team will take it very seriously. The critical window when a fetal heart block is most likely to develop occurs during the second trimester. To keep your baby safe, you will undergo a specialized monitoring protocol during this time.
Depending on your specific risk factors (like your antibody levels or pregnancy history), your doctors will tailor a surveillance plan. Many women are scheduled for fetal echocardiograms—specialized ultrasounds that look closely at the baby’s heart rhythm and structure—every week from week 16 to week 26 of pregnancy [6][19][20]. For lower-risk pregnancies, some specialists may opt for regular fetal heart rate checks using a Doppler instead of full weekly echocardiograms [21][22]. These appointments are usually handled by a Maternal-Fetal Medicine (MFM) specialist (a high-risk obstetrician) or a pediatric cardiologist.
This frequent monitoring allows your doctors to detect the very earliest signs of a heart block (such as a first-degree block). If a rhythm change is detected, your team can intervene immediately with specific medications—such as specialized steroids like dexamethasone that can cross the placenta to reach the baby [22][23][9]. Early intervention is crucial because early stages of heart block can sometimes be stabilized or reversed with these medications, whereas later stages are permanent [9][23].
After week 26, the risk of CHB developing drops dramatically. At that point, the frequency of specialized heart scans is usually reduced, and you will likely transition back to a more standard schedule of regular obstetric visits.
Frequently Asked Questions
What is the risk of my baby developing congenital heart block if I have Anti-SSA antibodies?
Does neonatal lupus mean my baby will have systemic lupus forever?
Should I take hydroxychloroquine (Plaquenil) during my pregnancy?
When is my baby at the highest risk for developing a heart block?
How will my doctor monitor my baby's heart during pregnancy?
Questions for Your Doctor
- • Given my specific Anti-SSA antibody levels, what is my personal risk profile for congenital heart block, and what monitoring protocol do you recommend?
- • Will I be referred to a Maternal-Fetal Medicine (MFM) specialist or a pediatric cardiologist for my heart rhythm monitoring?
- • Should my hydroxychloroquine dose be adjusted now that I am pregnant or as my pregnancy progresses?
- • If an early heart block or rhythm change is detected during an ultrasound, what is your specific plan for intervention?
Questions for You
- • Have I built a collaborative care team that includes my rheumatologist, my regular OB-GYN, and a high-risk obstetrician?
- • Am I mentally and logistically prepared for the time commitment of weekly or biweekly specialized appointments during my second trimester?
- • Have I communicated my specific anxieties about my baby's heart to my care team so they can provide the reassurance and information I need?
Want personalized information?
Type your question below to get evidence-based answers tailored to your situation.
References
- 1
Association between maternal anti-Ro and anti-La antibody levels and congenital heart block: a 20-year cohort study.
Pannain GD, Andrade JQ, Lopes MAB, et al.
Archives of gynecology and obstetrics 2026; (313(1)).
PMID: 41721052 - 2
Treatment options for preventing autoimmune-mediated congenital heart block: a systematic review.
Agarwal A, Skoutelis N, Zhou Y, et al.
Archives of disease in childhood 2025; (110(7)):556-565 doi:10.1136/archdischild-2024-327570.
PMID: 39890428 - 3
Outcome in 212 anti-Ro/SSA-positive pregnancies and population-based incidence of congenital heart block.
Skog A, Lagnefeldt L, Conner P, et al.
Acta obstetricia et gynecologica Scandinavica 2016; (95(1)):98-105 doi:10.1111/aogs.12785.
PMID: 26411741 - 4
Clinical Features, Autoantibodies, and Outcome of Neonatal Lupus Erythematosus.
Yang X
Fetal and pediatric pathology 2022; (41(3)):436-442 doi:10.1080/15513815.2020.1836097.
PMID: 33103534 - 5
Neonatal lupus: Follow-up in infants with anti-SSA/Ro antibodies and review of the literature.
Zuppa AA, Riccardi R, Frezza S, et al.
Autoimmunity reviews 2017; (16(4)):427-432 doi:10.1016/j.autrev.2017.02.010.
PMID: 28212920 - 6
Serial echocardiography for immune-mediated heart disease in the fetus: results of a risk-based prospective surveillance strategy.
Kan N, Silverman ED, Kingdom J, et al.
Prenatal diagnosis 2017; (37(4)):375-382 doi:10.1002/pd.5021.
PMID: 28177533 - 7
Sjögren's syndrome and pregnancy: a Portuguese case-control study.
Barros T, Braga J, Abreu MI, et al.
Reumatologia 2022; (60(5)):311-317 doi:10.5114/reum.2022.120754.
PMID: 36381208 - 8
Prenatal heart block screening in mothers with SSA/SSB autoantibodies: Targeted screening protocol is a cost-effective strategy.
Evers PD, Alsaied T, Anderson JB, et al.
Congenital heart disease 2019; (14(2)):221-229 doi:10.1111/chd.12713.
PMID: 30444309 - 9
Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.
Izmirly P, Kim M, Friedman DM, et al.
Journal of the American College of Cardiology 2020; (76(3)):292-302 doi:10.1016/j.jacc.2020.05.045.
PMID: 32674792 - 10
Current and future interventions for neonatal lupus: A review of the national library of Medicine's clinical trials database.
Buzzell A, French C, Po W, et al.
Lupus 2025; 9612033251412477 doi:10.1177/09612033251412477.
PMID: 41439852 - 11
Hydroxychloroquine in systemic lupus erythematosus, anti-SSA/SSB, and antiphospholipid antibody-positive pregnancies.
Saleh ZF, Somers EC, Romero VC, Marder W
American journal of obstetrics and gynecology 2026; (234(1)):7-20 doi:10.1016/j.ajog.2025.09.002.
PMID: 40930382 - 12
Autoimmune Congenital Heart Block: A Review of Biomarkers and Management of Pregnancy.
De Carolis S, Garufi C, Garufi E, et al.
Frontiers in pediatrics 2020; (8()):607515 doi:10.3389/fped.2020.607515.
PMID: 33415090 - 13
High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block.
Lisney AR, Szelinski F, Reiter K, et al.
Annals of the rheumatic diseases 2017; (76(8)):1476-1480 doi:10.1136/annrheumdis-2016-210927.
PMID: 28501799 - 14
No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine.
Friedman D, Lovig L, Halushka M, et al.
Clinical and experimental rheumatology 2017; (35(5)):857-859.
PMID: 28598777 - 15
Hydroxychloroquine in lupus or rheumatoid arthritis pregnancy and risk of major congenital malformations: a population-based cohort study.
Nguyen NV, Svenungsson E, Dominicus A, et al.
Rheumatology (Oxford, England) 2025; (64(1)):117-125 doi:10.1093/rheumatology/keae168.
PMID: 38479815 - 16
New Benefits of Hydroxychloroquine in Pregnant Women with Systemic Lupus Erythematosus: A Retrospective Study in a Tertiary Centre.
Abd Rahman R, Min Tun K, Kamisan Atan I, et al.
Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia 2020; (42(11)):705-711 doi:10.1055/s-0040-1715140.
PMID: 33254264 - 17
Impact of hydroxychloroquine on pregnancy outcomes in systemic lupus erythematosus: A 25 years retrospective cohort study from Asia.
Anees F, Dur-E-Shahwar , Raza A
Lupus 2026; 9612033261424329 doi:10.1177/09612033261424329.
PMID: 41656883 - 18
Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus.
Barsalou J, Costedoat-Chalumeau N, Berhanu A, et al.
Annals of the rheumatic diseases 2018; (77(12)):1742-1749 doi:10.1136/annrheumdis-2018-213718.
PMID: 30297329 - 19
Ambulatory Fetal Heart Monitoring: The New Kid on The Block?
Smith NA, Vinet É
Arthritis & rheumatology (Hoboken, N.J.) 2024; (76(3)):345-347 doi:10.1002/art.42757.
PMID: 37965716 - 20
Maternal and infant outcomes of pregnancy associated with anti-SSA/RO antibodies: a systematic review and meta-analysis.
Sheng X, Song X, Xiong Y, et al.
Pediatric rheumatology online journal 2023; (21(1)):22 doi:10.1186/s12969-023-00803-0.
PMID: 36870970 - 21
Reducing the burden of surveillance in pregnant women with no history of fetal atrioventricular block using the negative predictive value of anti-Ro/SSA antibody titers.
Kaizer AM, Lindblade C, Clancy R, et al.
American journal of obstetrics and gynecology 2022; (227(5)):761.e1-761.e10 doi:10.1016/j.ajog.2022.05.071.
PMID: 35690080 - 22
Dual challenge inside the womb: a case report of concomitant fetal atrio-ventricular block associated with maternal anti-SSA antibodies and fetal tachyarrhythmia diagnosed as Wolff-Parkinson-White syndrome after birth.
Chícharo AT, Rebelo M, Lopes AR, et al.
Frontiers in immunology 2024; (15()):1397103 doi:10.3389/fimmu.2024.1397103.
PMID: 39114649 - 23
Fetal-hope study: Home monitoring of fetal heart rate in SSA + pregnant women: Rationale and design.
Mauro A, Bizzi E, Caccia Dominioni C, et al.
European journal of obstetrics, gynecology, and reproductive biology 2024; (303()):99-103 doi:10.1016/j.ejogrb.2024.10.009.
PMID: 39454353
This page provides educational information about pregnancy with Anti-SSA antibodies. Always consult your maternal-fetal medicine specialist or rheumatologist for a personalized monitoring and treatment plan.
Stay up to date
Get notified when new research about Primary Sjögren's Syndrome is published.
No spam. Unsubscribe anytime.